PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

Trial Profile

PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 31 Oct 2015

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Docetaxel; Pertuzumab
  • Indications Early breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms PREDIX HER2
  • Most Recent Events

    • 09 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top